A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
- 21 January 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (12) , 2598-2609
Abstract
Purpose: Undetectable measurable residual disease (MRD) is a surrogate of prolonged survival in multiple myeloma. Thus, treatment individualization based on the probability of a patient achieving undetectable MRD with a singular regimen could represent a new concept toward personalized treatment, with fast assessment of its success. This has never been investigated; therefore, we sought to define a machine learning model to predict undetectable MRD at the onset of multiple myeloma. Experimental Design: This study included 487 newly diagnosed patients with multiple myeloma. The training (n = 152) and internal validation cohorts (n = 149) consisted of 301 transplant-eligible patients with active multiple myeloma enrolled in the GEM2012MENOS65 trial. Two external validation cohorts were defined by 76 high-risk transplant-eligible patients with smoldering multiple myeloma enrolled in the Grupo Español de Mieloma(GEM)-CESAR trial, and 110 transplant-ineligible elderly patients enrolled in the GEM-CLARIDEX trial. Results: The most effective model to predict MRD status resulted from integrating cytogenetic [t(4;14) and/or del(17p13)], tumor burden (bone marrow plasma cell clonality and circulating tumor cells), and immune-related biomarkers. Accurate predictions of MRD outcomes were achieved in 71% of cases in the GEM2012MENOS65 trial (n = 214/301) and 72% in the external validation cohorts (n = 134/186). The model also predicted sustained MRD negativity from consolidation onto 2 years maintenance (GEM2014MAIN). High-confidence prediction of undetectable MRD at diagnosis identified a subgroup of patients with active multiple myeloma with 80% and 93% progression-free and overall survival rates at 5 years. Conclusions: It is possible to accurately predict MRD outcomes using an integrative, weighted model defined by machine learning algorithms. This is a new concept toward individualized treatment in multiple myeloma. See related commentary by Pawlyn and Davies, p. 2482Keywords
All Related Versions
Funding Information
- Instituto de Salud Carlos III (CB16/12/00369, CB16/12/00400, CB16/12/00284)
- European Regional Development Fund-FEDER (PI15/01956, PI15/02049, FIS PI15/02062, PI18/01709, PI19/01451)
- European Union (FI21/00293)
- Cancer Research UK (C355/A26819)
- European Research Council (680200)
- CRIS Cancer Foundation (PR_EX_2020-02)
This publication has 38 references indexed in Scilit:
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myelomaBlood, 2018
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisLeukemia, 2018
- Minimal Residual Disease Negativity Is a New End Point of Myeloma TherapyJournal of Clinical Oncology, 2017
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myelomaLeukemia, 2017
- Next-generation multiple myeloma treatment: a pharmacoeconomic perspectiveBlood, 2016
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupJournal of Clinical Oncology, 2015
- A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease controlLeukemia, 2013
- EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocolsLeukemia, 2012
- The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBlood, 2009
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005